NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED
STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE
PEOPLE'S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE
DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE.
PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT

Reference is made to the stock exchange announcement published by BerGenBio ASA
(the "Company") earlier today, on 25 April 2023, regarding the resolution by the
Company's board of directors to propose that the Company carries out a share
capital increase, by way of a partly underwritten rights issue, to raise gross
proceeds of up to NOK 250 million (the "Rights Issue").

Date on which the terms and conditions of the preferential rights issue were
announced: 25 April 2023

Last day including right: 22 May 2023

Ex-date: 23 May 2023

Record Date: 24 May 2023

Date of approval: 22 May 2023

Maximum number of new shares: 2,500,000,000

Subscription price: Minimum NOK 0.10 and maximum NOK 10

Ratio preferential rights: To be announced when the final number of new shares
is determined

Subscription ratio: To be announced when the final number of new shares is
determined

Managers: Arctic Securities AS and Carnegie AS

Will the rights be listed: The Company will apply for listing of the
preferential rights on the Oslo Stock Exchange

ISIN for the preferential rights: To be announced when clarified

Other information: The subscription price for the new shares to be issued in the
Rights Issue, and thus the final number of new shares and the exact amount of
the share capital increase will be proposed by the board of directors, based on
a recommendation from the managers, the day prior to the annual general meeting
to be held on 22 May 2023 (the "AGM"). See the stock exchange announcement
published earlier today, on 25 April 2023, for further information regarding the
Rights Issue. The rights issue is subject to approval by the AGM. Notice of the
AGM will be sent on 28 April 2023.

This information is published in accordance with the requirements of the
Continuing Obligations.

For further information, please contact:

Martin Olin CEO, BerGenBio ASA

ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA

rune.skeie@bergenbio.com

Investor Relations / Media Relations

Graham Morrell

graham.morrell@bergenbio.com

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including cancer and severe respiratory infections. The
Company is focused on its proprietary lead candidate bemcentinib a potentially
first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC
and COVID-19.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
Company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit www.bergenbio.com.